Sorafenib for the treatment of multiple myeloma

Massimo Gentile, Massimo Martino, Anna Grazia Recchia, Ernesto Vigna, Lucio Morabito, Fortunato Morabito

Research output: Contribution to journalArticlepeer-review


Introduction: Sorafenib is an orally available compound that acts predominantly by targeting the Ras/Raf/MEK/ERK pathway and by inhibiting the vascular endothelial growth factor (VEGF). Since the Ras/Raf/MEK/ERK pathway is implicated in the proliferation of multiple myeloma (MM) cells and VEGF in bone marrow neovascularization, sorafenib is a drug offering the potential for targeting two important pathogenetic mechanisms involved in MM. Thus, sorafenib is being proposed for use in MM. Areas covered: In this review, the authors discuss the rationale for the use of sorafenib in MM. They then summarize the clinical development of sorafenib in MM, from initial Phase I to Phase II studies. A systematic literature review of the trials was performed using PubMed. Expert opinion: Preliminary data from phase I/II trials showed that sorafenib had a good safety profile but minimal anti-myeloma activity as a single agent in relapsed/refractory patients. Results of phase II trials, evaluating sorafenib combined with new drugs, such as bortezomib and lenalidomide are eagerly awaited.

Original languageEnglish
Pages (from-to)1-7
Number of pages7
JournalExpert Opinion on Investigational Drugs
Publication statusAccepted/In press - Apr 5 2016


  • Myeloma
  • Raf inhibitor
  • sorafenib
  • target therapy

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Sorafenib for the treatment of multiple myeloma'. Together they form a unique fingerprint.

Cite this